Gilead Sciences CEO John Milligan was already set to collect a smaller pay package than his predecessor John Martin did. After all, Martin did hold down that job for more than 20 years. But it turns out Milligan’s compensation shrank …
Stock
Gilead's stock has so far failed to take part in the broader biotech rally this year due to a continually worsening outlook for its hepatitis C franchise. In the first quarter of this year, for example, the company missed consensus estimates on …
Lag
Jim Cramer makes the calls on Tanger Factory Outlet Centers, Gilead Sciences, and Qorvo in the 'Mad Money' Lightning Round. President Trump delivered some good news to tech giants and other corporations hoarding loads of cash abroad …
Earnings
Gilead Sciences's dividend payout ratio is now 18.91%. Gilead Sciences Inc. (GILD) topped its 52-week high price of $89.12 on Obsolete and 52-Week Low Price of $65.38 on Obsolete. GILD has recorded a 50-day average of $67.30 and …
Q1
Many value investors have flocked to Gilead as the world’s top biotech stock now that it is valued at a lower multiple than Big Pharma rivals. 24/7 Wall St. recently highlighted 21 value stocks in the S&P 500 Index in which the value was …
Wall Street
Gilead’s stock now trades at a high-single digit price-to-earnings multiple which typically has many bargain hunters salivating, especially in a market where many quality blue-chip stocks and dividend aristocrats trade at over 20x …
Dividend
Gilead Sciences, Inc. (NASDAQ:GILD) Director John Francis Cogan sold 9,943 shares of the stock in a transaction that occurred on Tuesday, May 9th. The stock was sold at an average price of $67.25, for a total transaction of $668,666.75. …
Gilead Sciences has been a dream stock for long-term investors. Anyone who was smart enough to get in at the IPO in 1992 and hold the stock until today are sitting on a gain of around 17,000%! That kind of performance is simply …
Today's Most Active Call & Put Options of the S&P 500 » Cognizant Technology Solutions Corp. (CTSH) options are showing a volume of 20,918 contracts thus far today. That number of contracts represents approximately 2.1 million …
Wednesday
Gilead Sciences Inc. (NSDQ:GILD) stock is up over 4% last week since its Q3 earnings on November 1st. The company was definitely helped by Donald Trump winning the presidential election as the biotech sector as a whole took off once …